TY - JOUR
T1 - Hope Hp-GC Project—Program Implementation for Primary and Secondary Prevention of Gastric Cancer in Latin America
AU - the Task Force HOPE Hp-GC Project Consortium
AU - Uribe, Javier
AU - Portillo-Miño, José Darío
AU - Latorre, Gonzalo
AU - Reyes-Placencia, Diego
AU - Pizarro, Mauricio
AU - Vargas, José Ignacio
AU - Espino, Alberto
AU - Jure, Camila
AU - Pizarro, Margarita
AU - Bofill, Gabriela
AU - Silva, Felipe
AU - Palacios, Nilton
AU - Díaz-Garrido, Natalia
AU - Huidobro, Laura
AU - Araya, Raúl
AU - Ledesma, Sergio
AU - Otero, William
AU - Otero, Lina
AU - Remes-Troche, José M.
AU - Campos, Christian
AU - Largacha, Monserrate
AU - Varas, Oscar
AU - Cabrera, Dacio
AU - Piscoya, Alejandro
AU - Ramírez, Juan
AU - Laudanno, Oscar
AU - Esteves, Sebastián
AU - Cifuentes, Sandra
AU - García, Eduardo
AU - María-Guzmán, Ana
AU - Morgan, Douglas
AU - Espinoza, Manuel
AU - Shah, Shailja C.
AU - Park, Jin Young
AU - Camargo, M. Constanza
AU - Riquelme, Arnoldo
AU - Frías, Juan Sebastián
AU - Marulanda, Hernando
AU - Bolaños, Karla
AU - Montenegro, Francia
AU - Arcos, Mónica
AU - Rubiano, Yaneth
AU - Guerrero, Angela
AU - López, Juan Carlos
AU - Montenegro, Franco
AU - Rosero-Galindo, Carol Yovanna
AU - Cano-Contreras, Ana Delfina
AU - Vilca, Braulio Guillén
AU - Vargas, Guillermo
AU - Castrillo, Óscar Varas
N1 - © 2026 John Wiley & Sons Ltd.
PY - 2026/3
Y1 - 2026/3
N2 - Introduction: Gastric cancer (GC) is the fifth leading cause of cancer-related mortality globally; its main burden is concentrated in East Asia and some areas of Europe and Latin America. This study aims to develop an organized and structured GC prevention pilot program in intermediate-to-high-incidence countries in Latin America. Methods: This study involved two strategies: (a) primary prevention for screen-and-treat H. pylori infection among individuals aged 30–39 years (n = 7500, 500 in 15 sites), and (b) primary and secondary prevention for individuals aged 40–75 years (n = 9600, 600 in 16 sites) with tiered risk stratification using an algorithm developed and validated in Chile (Gastrocalc: priority 1 to 6; age, sex, hypertension, IgG H. pylori, pepsinogen I and II, and Gastrin-17b), and high-quality esophagogastroduodenoscopy (EGD) evaluation. Results: Pilot phases were successfully conducted in Chile and Colombia during 2023–2025. In Chile (Molina), 4152 asymptomatic individuals were tested with H. pylori prevalence of 46% (n = 113/246) in 2023, 34% (n = 504/1484) in 2024, and 32% (n = 609/1904) in 2025. The H. pylori prevalence among individuals aged 30–39 years (592/4152; 14.3%) was 37.8%. In Colombia, 1250 asymptomatic individuals were screened across four regions; in 2025, the prevalence of H. pylori among individuals aged 30–39 years was 69% (n = 895/1250). The validation of Gastrocalc included 866 individuals from 5 regions in Chile. The algorithm successfully identified 80.6% of OLGA III–IV patients and 100% of GC patients (Priority 1–4). Other countries will start activities in 2026. Conclusions: This pioneering study will advance understanding and feasibility of urgently needed primary and secondary prevention for GC in Latin America.
AB - Introduction: Gastric cancer (GC) is the fifth leading cause of cancer-related mortality globally; its main burden is concentrated in East Asia and some areas of Europe and Latin America. This study aims to develop an organized and structured GC prevention pilot program in intermediate-to-high-incidence countries in Latin America. Methods: This study involved two strategies: (a) primary prevention for screen-and-treat H. pylori infection among individuals aged 30–39 years (n = 7500, 500 in 15 sites), and (b) primary and secondary prevention for individuals aged 40–75 years (n = 9600, 600 in 16 sites) with tiered risk stratification using an algorithm developed and validated in Chile (Gastrocalc: priority 1 to 6; age, sex, hypertension, IgG H. pylori, pepsinogen I and II, and Gastrin-17b), and high-quality esophagogastroduodenoscopy (EGD) evaluation. Results: Pilot phases were successfully conducted in Chile and Colombia during 2023–2025. In Chile (Molina), 4152 asymptomatic individuals were tested with H. pylori prevalence of 46% (n = 113/246) in 2023, 34% (n = 504/1484) in 2024, and 32% (n = 609/1904) in 2025. The H. pylori prevalence among individuals aged 30–39 years (592/4152; 14.3%) was 37.8%. In Colombia, 1250 asymptomatic individuals were screened across four regions; in 2025, the prevalence of H. pylori among individuals aged 30–39 years was 69% (n = 895/1250). The validation of Gastrocalc included 866 individuals from 5 regions in Chile. The algorithm successfully identified 80.6% of OLGA III–IV patients and 100% of GC patients (Priority 1–4). Other countries will start activities in 2026. Conclusions: This pioneering study will advance understanding and feasibility of urgently needed primary and secondary prevention for GC in Latin America.
KW - early detection of cancer
KW - gastric cancer
KW - Helicobacter pylori
KW - long-term effects
KW - premalignant conditions
KW - prevention
KW - screen-and-treat
KW - Primary Prevention/methods
KW - Prevalence
KW - Humans
KW - Middle Aged
KW - Chile/epidemiology
KW - Male
KW - Colombia/epidemiology
KW - Latin America/epidemiology
KW - Pilot Projects
KW - Helicobacter Infections/epidemiology
KW - Secondary Prevention/methods
KW - Stomach Neoplasms/prevention & control
KW - Adult
KW - Female
KW - Aged
UR - https://www.scopus.com/pages/publications/105036137355
U2 - 10.1111/hel.70109
DO - 10.1111/hel.70109
M3 - Article
C2 - 42002545
AN - SCOPUS:105036137355
SN - 1083-4389
VL - 31
JO - Helicobacter
JF - Helicobacter
IS - 2
M1 - e70109
ER -